NCT04427306View on ClinicalTrials.gov

Neoadjuvant T-VEC in High Risk Early Melanoma

PHASE2SuspendedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

May 21, 2020

Primary Completion Date

June 27, 2022

Study Completion Date

May 21, 2024

Conditions

Melanoma

Interventions

DRUG

T-Vec

(talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery

Trial Locations (1)

95817

UC Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

University of California, Davis

OTHER